Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient.
暂无分享,去创建一个
A. Bertoletti | M. Brunetto | A. Thrasher | M. Maini | W. Qasim | A. Gehring | S. Xue | A. Khakpoor | H. Zhan | P. Ciccorossi | K. Gilmour | D. Cavallone | F. Moriconi | F. Farzhenah | A. Mazzoni | L. Chan | E. Morris | F. Bonino | H. Stauss | Anna Schurich
[1] Christian Stemberger,et al. Lowest numbers of primary CD8(+) T cells can reconstitute protective immunity upon adoptive immunotherapy. , 2014, Blood.
[2] H. Chan,et al. Viral-human chimeric transcript predisposes risk to liver cancer development and progression. , 2014, Cancer cell.
[3] A. Bertoletti,et al. Building and Optimizing a Virus-specific T Cell Receptor Library for Targeted Immunotherapy in Viral Infections , 2014, Scientific Reports.
[4] D. Campana,et al. A Practical Approach to Immunotherapy of Hepatocellular Carcinoma Using T Cells Redirected Against Hepatitis B Virus , 2013, Molecular therapy. Nucleic acids.
[5] P. Veys,et al. Production and First-in-Man Use of T Cells Engineered to Express a HSVTK-CD34 Sort-Suicide Gene , 2013, PloS one.
[6] Tongguang Wang,et al. Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy , 2013, Journal of immunotherapy.
[7] Angela M. Liu,et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma , 2012, Nature Genetics.
[8] H. El‐Serag,et al. Epidemiology of viral hepatitis and hepatocellular carcinoma. , 2012, Gastroenterology.
[9] S. Rosenberg,et al. Treating cancer with genetically engineered T cells. , 2011, Trends in biotechnology.
[10] A. Bertoletti,et al. Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. , 2011, Journal of hepatology.
[11] P. MacAry,et al. Targeting Hepatitis B Virus-Infected Cells with a T-Cell Receptor-Like Antibody , 2010, Journal of Virology.
[12] Bruce R. Blazar,et al. Engineering lymphocyte subsets: tools, trials and tribulations , 2009, Nature Reviews Immunology.
[13] A. Bertoletti,et al. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma. , 2009, Gastroenterology.
[14] S. Rosenberg,et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.
[15] D. Samuel,et al. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. , 2008, Gastroenterology.
[16] Geoffrey Dusheiko,et al. Longitudinal Analysis of CD8+ T Cells Specific for Structural and Nonstructural Hepatitis B Virus Proteins in Patients with Chronic Hepatitis B: Implications for Immunotherapy , 2004, Journal of Virology.
[17] D. Vergani,et al. Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. , 1999, Gastroenterology.
[18] Christine Pourcel,et al. Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma , 1980, Nature.